Phase 2 Grant definition

Phase 2 Grant means £VALUE being the maximum amount of grant payable to the Grant Recipient by the Council during Phase 2 of the Refurbishment Programme in accordance with the provisions of Schedule 1
Sample 1Sample 2Sample 3
Phase 2 Grant means a Grant for which a Participating Kabupaten is eligible to apply in respect of Sub-projects: (i) upon its satisfying the eligibility criteria set forth in: (x) the Local Governance Reform Framework for the provision of said grants to Participating Kabupatens in the twelve (12) month period following that covered by Phase 1 Grants; and (y) Part 2 of Annex B to Schedule 4 of this Agreement; and (ii) in accordance with the relevant provisions concerning said Grants in the Project Operational Manual, which Sub-projects are to be financed in the Fiscal Year immediately following the attainment of such eligibility; and “Phase 2 Grants” means Phase 2 Grants collectively.
Sample 1

Examples of Phase 2 Grant in a sentence

  • SME Instrument Phase 1 and SME Instrument Phase 2 each have their own specific Grant Agreements (see annotated specific SME Instrument Phase 1 Grant Agreement and annotated specific SME Instrument Phase 2 Grant Agreement).

  • HAPP Phase 2 Reopened is designed to allow more time for applicants to submit funding requests based on the HAPP Phase 2 award guidance in light of the recent COVID-19 surges facing Rhode Island hospitals.Previous applicants may elect to update and resubmit their HAPP Phase 2 Grant applications or carry forward their prior HAPP Phase 2 Grant application.

  • This form is provided at this time for informational purposes only.)Annex D – Phase 2 Grant Budget Template (To be completed and submitted only by the applicants selected to proceed to Phase 2.

  • The application requires completion and submission of all of the following materials unless the applicant elects to carry forward their prior HAPP Phase 2 Grant application.

  • The report notified the Sub-Committee of the termination of the Phase 2 Grant Delivery Contract following LIF review recommendation from the Mayor, and to formally close this grant.

  • We are satisfied that the allocation of the Phase 2 Grant was not to the detriment of any group with a Protected Characteristic.

  • The Equality, Diversity and Inclusion adviser to the Governance Committee, Dr Miriam Lynn was satisfied that the allocation of the Phase 2 Grant was not to the detriment of any group with a Protected Characteristic.

  • ANNEXES Annex A – Phase 1 Grant Idea Snapshot Form (To be completed and submitted by all applicants participating in Phase 1)Annex B – Phase 1 Required Certifications (To be completed and submitted by all applicants participating in Phase 1)Annex C – Phase 2 Grant Concept Paper Form (To be completed and submitted only by the applicants selected to proceed to Phase 2.

  • This work is scheduled to be completed in October 2022, allowing for full expenditure of the grant funds prior to 31st December 2022.The WaRM Phase 2 Grant is on track to be completed by the initial completion date of 30th June 2023.

  • Mr. Gomez updated the Board that aside from the from the normal appropriations we were awarded 5 million dollars which include 1.5 million for the Accelerator Program, 1.5 for the Small Business Innovation Research (SBIR) Phase 2 Grant, 1 million for the Manufacturing Assistance Program (MAP) Program and 1 million for the Hawaii Office of Naval Research (HONR) Program.

Related to Phase 2 Grant

  • Phase 2 means the phase of the ATP comprised of: (1) improvements to the State Street Substation to receive Rebuilt Line 972; (2) the rebuilding of NYSEG’s existing Line 972 not performed in Phase 1; (3) construction of Relocated Line 15; (4) the construction of Bused Line 5; (5) improvements to the Elbridge Substation to receive Relocated Line 15; and (6) improvements to the Elbridge Substation to receive Bused Line 5.

  • Phase 1 Study means a clinical study of a drug candidate in human patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. §312.21(a), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The drug candidate can be administered to patients as a single agent or in combination with other investigational or marketed agents.

  • Phase 1 means the phase of the ATP comprised of: (1) improvements to the State Street Substation; (2) construction of the Proposed Line; (3) the rebuilding of NYSEG’s existing Lines 971 and 000 xxxxx xx Xxxxxxxx Xxxx xx the NYSEG ROW to allow for construction of the Proposed Line as intended; (4) improvements to the Elbridge Substation to accept the Proposed Line; and (5) National Grid’s conveyance to NYSEG of the NYSEG Acquired ROW and such other land interests as contemplated by the Purchase and Sale Agreement.

  • Phase 2 Trial means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. §312.21(b) (including any such clinical study in any country other than the United States).

  • Continuous Improvement Plan means a plan for improving the provision of the Goods and/or Services and/or reducing the Charges produced by the Supplier pursuant to Framework Schedule 12 (Continuous Improvement and Benchmarking);

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Phase II Study means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Phase 3 means the period commencing on the day after the Phase 2 implementation date and ending on the Phase 3 implementation date (as defined below).

  • Area Plan or “multiyear area plan” means a document, developed in accordance with the uniform area plan format and IAPI issued by the department, that is submitted to the department every four years, with annual updates, by an AAA in order to receive subgrants from the department’s grants.

  • Phase 1 Trial means, with respect to a Licensed Product, a clinical trial (or — in case of a multi-phase clinical trial — those parts of a clinical trial) in line with the provisions of 21CFR312, Section 21 (a).

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Annual Work Plan means each work plan approved by the Association under Section I.C of Schedule 2 to this Agreement for inclusion in the Project.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase 3 Study means a clinical study of a drug candidate in human patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.

  • Work Plan means a plan that describes each individual activity to be conducted to complete eligible activities and the associated costs of each individual activity.

  • Vesting Commencement Date means the Grant Date or such other date selected by the Committee as the date from which an Award begins to vest.

  • Phase III means human clinical trials, the principal purpose of which is to establish substantial evidence of both safety and efficacy in patients with the disease or condition being studied, as more fully defined in 21 C.F.R. §312.21(c) or similar clinical study in a country other than the United States. Phase III shall also include any other human clinical trial intended to serve as a pivotal trial to support the submission of an application for regulatory approval.

  • Phase II means the second part of the tuition incentive assistance program which provides assistance in the third and fourth year of 4-year degree programs.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Development Phase means the period before a vehicle type is type approved.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.